We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.43 | -6.33865248227 | 22.56 | 23.57 | 19.8375 | 937837 | 20.86701703 | CS |
4 | 2.62 | 14.1545110751 | 18.51 | 25.65 | 18.2 | 392782 | 21.35353838 | CS |
12 | -3.63 | -14.6607431341 | 24.76 | 31.13 | 18.2 | 225037 | 23.05172747 | CS |
26 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184107 | 23.19678156 | CS |
52 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184107 | 23.19678156 | CS |
156 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184107 | 23.19678156 | CS |
260 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184107 | 23.19678156 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions